Studies have shown that GLP-1 agonists can trigger effects in the brain, the heart, the liver, the pancreas, the stomach, and the musclesmeaning that they could have implications for conditions other than type 2 diabetes and obesity, such as heart disease, kidney disease, liver disease, and even neurological conditions such as Alzheimer's disease
The scale does not distinguish between fat loss and muscle loss
It works as a 5-alpha reductase inhibitor, alpha-blocker, and immunomodulator for complete prostate care
Moreover, some NAD + precursors have shown side effects, such as the use of NA at certain doses that might be limited due to skin flushing or induction of insulin resistance 332,333
Multifaced roles of the v3 integrin in ehlers-danlos and arterial tortuosity syndromes' dermal fibroblasts